DrugPatentWatch Database Preview

Details for Patent: 6,602,911

Which drugs does patent 6,602,911 protect, and when does it expire?

Patent 6,602,911 protects SAVELLA and is included in one NDA.

This patent has fourteen patent family members in nine countries.

Summary for Patent: 6,602,911

Title:	Methods of treating fibromyalgia
Abstract:	The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s):	Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA)
Assignee:	Cypress Bioscience, Inc. (San Diego, CA)
Application Number:	10/028,547
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 6,602,911

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Allergan Sales Llc	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-001	Jan 14, 2009	AB	RX	Yes	No	➤ Sign Up	➤ Sign Up				MANAGEMENT OF FIBROMYALGIA (FM)	➤ Sign Up
Allergan Sales Llc	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-002	Jan 14, 2009	AB	RX	Yes	No	➤ Sign Up	➤ Sign Up				MANAGEMENT OF FIBROMYALGIA (FM)	➤ Sign Up
Allergan Sales Llc	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-003	Jan 14, 2009	AB	RX	Yes	Yes	➤ Sign Up	➤ Sign Up				MANAGEMENT OF FIBROMYALGIA (FM)	➤ Sign Up
Allergan Sales Llc	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-004	Jan 14, 2009	AB	RX	Yes	No	➤ Sign Up	➤ Sign Up				MANAGEMENT OF FIBROMYALGIA (FM)	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 6,602,911

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,820,643	Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain	➤ Sign Up
7,888,342	Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain	➤ Sign Up
6,635,675	Method of treating chronic fatigue syndrome	➤ Sign Up
7,915,246	Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 6,602,911

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	552856	➤ Sign Up
Australia	2003268020	➤ Sign Up
Canada	2467356	➤ Sign Up
Canada	2493490	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 6,602,911

For more information try a trial or see the plans and pricing